Innovative Health Care Portfolio, Series 22
Ticker Symbol: FFVRMX
40 Holdings (As of Day of Deposit) |
Ticker |
Name |
Initial
Weight |
Price* |
Biotechnology (37.50%) |
ABBV |
AbbVie Inc. |
2.50% |
$199.35 |
ALNY |
Alnylam Pharmaceuticals, Inc. |
2.48% |
256.21 |
AMGN |
Amgen Inc. |
2.43% |
328.93 |
BIIB |
Biogen Inc. |
2.51% |
200.64 |
BMRN |
BioMarin Pharmaceutical Inc. |
2.51% |
84.85 |
EXEL |
Exelixis, Inc. |
2.50% |
26.31 |
GILD |
Gilead Sciences, Inc. |
2.50% |
81.44 |
HALO |
Halozyme Therapeutics, Inc. |
2.50% |
59.26 |
INCY |
Incyte Corporation |
2.52% |
63.13 |
MRNA |
Moderna, Inc. |
2.48% |
79.28 |
NBIX |
Neurocrine Biosciences, Inc. |
2.51% |
119.10 |
REGN |
Regeneron Pharmaceuticals, Inc. |
2.59% |
1136.35 |
SRPT |
Sarepta Therapeutics, Inc. |
2.53% |
126.94 |
UTHR |
United Therapeutics Corporation |
2.53% |
342.46 |
VRTX
|
Vertex Pharmaceuticals Incorporated
|
2.41%
|
470.78
|
Health Care Equipment (27.43%) |
BSX |
Boston Scientific Corporation |
2.51% |
83.06 |
EW |
Edwards Lifesciences Corporation |
2.48% |
67.14 |
GMED |
Globus Medical, Inc. |
2.49% |
69.38 |
HOLX |
Hologic, Inc. |
2.52% |
81.96 |
PODD |
Insulet Corporation |
2.45% |
226.50 |
ISRG |
Intuitive Surgical, Inc. |
2.48% |
484.24 |
PHG |
Koninklijke Philips N.V. |
2.50% |
29.72 |
MASI |
Masimo Corporation |
2.49% |
114.99 |
MDT |
Medtronic Plc |
2.49% |
90.99 |
STE |
Steris Plc |
2.53% |
247.17 |
SYK
|
Stryker Corporation
|
2.49%
|
365.05
|
Health Care Technology (5.03%): |
EVH |
Evolent Health, Inc. |
2.50% |
30.30 |
VEEV
|
Veeva Systems Inc.
|
2.53%
|
221.89
|
Life Sciences Tools & Services (10.00%): |
ILMN |
Illumina, Inc. |
2.47% |
124.13 |
IQV |
IQVIA Holdings Inc. |
2.54% |
235.20 |
RGEN |
Repligen Corporation |
2.50% |
146.70 |
TMO
|
Thermo Fisher Scientific Inc.
|
2.49%
|
624.21
|
Managed Health Care (2.51%) |
HQY
|
HealthEquity, Inc.
|
2.51%
|
74.69
|
Pharmaceuticals (17.53%) |
AZN |
AstraZeneca Plc |
2.49% |
81.16 |
LLY |
Eli Lilly and Company |
2.56% |
901.25 |
JNJ |
Johnson & Johnson |
2.48% |
167.38 |
LGND |
Ligand Pharmaceuticals Inc. |
2.50% |
102.23 |
MRK |
Merck & Co., Inc. |
2.49% |
115.33 |
NVO |
Novo Nordisk A/S |
2.51% |
129.78 |
ZTS |
Zoetis Inc. |
2.50% |
191.36 |
* As of the close of business on 9/10/24.
Market values are for reference only and are not indicative of your individual
cost basis.
Not FDIC Insured Not Bank Guaranteed May Lose Value |
Portfolio Summary |
Initial Date of Deposit |
9/11/2024 |
Initial Public Offering Price |
$10.00 per Unit |
Portfolio Ending Date |
12/11/2025 |
Cash CUSIP |
30337N100 |
Reinvestment CUSIP |
30337N118 |
Fee Account Cash CUSIP |
30337N126 |
Fee Account Reinvestment CUSIP |
30337N134 |
Fee Table (based on a $10 public offering
price per unit) |
|
Standard |
Fee/Wrap |
Deferred Sales Charge |
1.35% |
— |
Creation & Development Fee (C&D Fee) |
0.50% |
0.50% |
Maximum Sales Charge |
1.85% |
0.50% |
|
|
|
Estimated Organization Costs |
0.510% |
0.510% |
Estimated Annual Trust Operating Expenses |
0.215% |
0.215% |
The deferred sales charge will be deducted in three monthly installments commencing 12/20/24. When
the public offering price is less than or equal to $10.00 per unit, there will be no initial sales charge. If the
price exceeds $10.00 per unit, you will pay an initial sales charge. The C&D fee is a charge of $0.050 per unit
collected at the end of the initial offering period. If the price you pay exceeds $10.00 per unit, the C&D fee
will be less than 0.50%; if the price you pay is less than $10.00 per unit, the C&D fee will exceed 0.50%.
Estimated organization costs will be deducted from the assets of the trust at the end of the initial offering
period. Estimated organization costs and trust operating expenses are assessed on a fixed dollar amount per
unit basis which, as a percentage of average net assets, will vary over time. Actual expenses may be more or
less than the estimates. Please see “Fee Table” in the trust prospectus for additional information.
You should consider the portfolio's investment objectives, risks, and
charges and expenses carefully before investing. Contact your financial professional
or call First Trust Portfolios, L.P. at 1.800.621.1675 to request a prospectus,
which contains this and other information about the portfolio. Read it carefully
before you invest.
Risk Considerations
An investment in this unmanaged unit investment trust should be
made with an understanding of the risks involved with owning common stocks, such as an economic
recession and the possible deterioration of either the financial condition of the issuers of the equity
securities or the general condition of the stock market.
You should be aware that the portfolio is concentrated in stocks in the health care sector which involves additional risks, including limited diversification. The companies engaged in the health care sector are subject to fierce
competition, high research and development costs, governmental regulations, loss of patent protection, and changing consumer spending trends. In addition, health crises, such as a pandemic outbreak, can severely impact
the health care industry in particular.
Securities of non-U.S. issuers are subject to additional risks, including currency fluctuations, political risks, withholding, the lack of adequate financial information, and exchange control restrictions impacting non-U.S. issuers.
An investment in a portfolio containing small-cap and mid-cap companies is subject to additional
risks, as the share prices of small-cap companies and certain mid-cap companies are often more
volatile than those of larger companies due to several factors, including limited trading volumes,
products, financial resources, management inexperience and less publicly available information.
Large capitalization companies may grow at a slower rate than the overall market.
As the use of Internet technology has become more prevalent in the course of business, the trust has become
more susceptible to potential operational risks through breaches in cybersecurity.
Ongoing armed conflicts between Russia and Ukraine in Europe and among Israel, Hamas and other militant groups in the Middle East, have caused and could continue to cause significant market disruptions and volatility
within the markets in Russia, Europe, the Middle East and the United States. The hostilities and sanctions resulting from those hostilities could have a significant impact on certain investments as well as performance.
The ongoing effects of the COVID-19 global pandemic, or the potential impacts of any future public health crisis, may cause significant volatility and uncertainty in global financial markets. While vaccines have been developed, there is no guarantee that vaccines will be effective against future variants of the disease.
The value of the securities held by the trust may be subject to steep declines or increased volatility
due to changes in performance or perception of the issuers.
This UIT is a buy and hold strategy and investors should consider their ability to hold the trust until maturity. There may be tax consequences unless units are purchased in an IRA or other qualified plan.